ENDRA Life Sciences Inc.
NDRA
$4.87
$0.020.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 38.93% | 9.20% | 8.36% | 1.26% | -14.39% |
| Total Depreciation and Amortization | -23.71% | -25.70% | -24.68% | -24.58% | -25.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -55.80% | 37.91% | 149.29% | 113.69% | 224.92% |
| Change in Net Operating Assets | -83.07% | 121.12% | 106.55% | 105.35% | 114.52% |
| Cash from Operations | 29.97% | 36.89% | 38.01% | 28.71% | 22.50% |
| Capital Expenditure | -8.13% | 24.45% | 24.45% | 81.42% | 52.80% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -100.00% | -65.22% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -23,472.66% | -64.76% | -64.76% | 70.70% | 48.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | 100.00% | -- |
| Issuance of Common Stock | -37.39% | -70.88% | -75.81% | 26.13% | 41.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -156.54% | -100.00% | -100.00% | -100.00% |
| Cash from Financing | -26.59% | -87.84% | -90.51% | -6.28% | 3.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -723.63% | -380.08% | -390.40% | 176.21% | 119.25% |